ESTRO 2024 - Abstract Book

S869

Clinical - CNS

ESTRO 2024

Optical Surface Monitoring System(OSMS)

3.9%

22.8%

69.2%

2.36%

1.57%

Conclusion:

Our preliminary analysis showed that the specialists dedicated to SNC tend to favor SRS in almost all the scenarios. Further analysis will be hold to better address the ongoing trends.

Keywords: Survey, multiple brain metastases, AIRO

1903

Digital Poster

Evaluating outcomes of adjuvant temozolomide pre and post radiotherapy in high grade glioma.

Subhash Gupta 1 , Arun T 1 , Haresh K Parambath 1 , Anjali V Ramdulari 1 , Aswin Ravi 1 , Manoj Phalak 2 , Vivek Tandon 2 , Vaishali Suri 3 , Mehr C Sharma 3 1 All India Institute of Medical Sciences, Department of Radiation Oncology, New Delhi, India. 2 All India Institute of Medical Sciences, Department of NeuroSurgery, New Delhi, India. 3 All India Institute of Medical Sciences, Department of Pathology, New Delhi, India

Purpose/Objective:

Post-operative concurrent chemo radiotherapy followed by adjuvant Temozolomide (TMZ) is the current standard of care in high – grade glioma. Timely initiation of post operative radiotherapy within 4-6 weeks plays a crucial role in treatment outcomes, but unavoidable delays sometimes occur due to post operative complications or patient recovery timelines. One possible solution to mitigate the impact of these delays is to initiate adjuvant TMZ early, effectively bridging the time gap. This study aimed to assess the treatment outcomes in patients with newly diagnosed biopsy proven high grade glioma who received adjuvant temozolomide pre and post radiotherapy.

Material/Methods:

Patients with biopsy proven high grade glioma were included in this retrospective study. Progression free survival (PFS) was defined as the time interval from the date of surgery to the date of disease progression. Overall survival (OS) was defined from the date of surgery to the last follow-up or death. Time to event data was evaluated using Kaplan. -Meier method.

Results: